Browse by category

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to research, ‘Bariatric surgery effectiveness after glp-1 agonist weight loss (abstract id: 4149)’, presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery. “Patients are increasingly having surgery after GLP-1 therapy,

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to research, ‘Understanding insurance-based differential healthcare costs for GLP-1ra versus bariatric surgery (abstract id: 4339)’, presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery. “As GLP-1 use bec

Metabolic and bariatric surgery dramatically improves outcomes for patients with obesity and chronic kidney disease (CKD), significantly reducing the risk of kidney failure, major cardiovascular events (MACE) and death, according to research, ‘Long-term renal and survival outcomes in patients with obesity and chronic kidney disease following metabolic and bariatric surgery: A Trinetx cohort study (Abstract ID: 4520)’ presented at the annual meeting of the American Society for

Both metabolic and bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonist (GLP-1RA) medications improve cardiovascular health in people with obesity, but surgery was associated with significantly greater reductions in long-term cardiovascular risk, according to a study by researchers from the Mayo Clinic. Importantly, researchers say the findings are not about choosing one treatment over another, but about better aligning treatment decisions with long-term healt

A systematic review and meta-analysis has indicated that bariatric surgery may reduce the overall risk of breast cancer in women with obesity, according to researchers from China. However, the studies also revealed a paradoxical finding: Despite the overall reduction in risk, the incidence of stage I breast cancer increased in the surgical group. Nevertheless, the study authors acknowledge that as the studies are based on observational data, a causal relationship cannot be co

There has been a 16-fold increase in the use of weight loss drugs among patients before metabolic and bariatric surgery, signalling an...

In patients with steatotic liver disease (SLD), metabolic bariatric surgery (MBS) is associated with significant reductions in the rates...

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo metabolic and bariatric surgery (MBS)...

A study led by investigators at Mass General Brigham has found that adding semaglutide and tirzepatide to usual care represents a...

Eating disorders (EDs) are highly prevalent among metabolic bariatric surgery (MBS) patients, with binge eating disorder (BED) being the...